Tenpoint Therapeutics received FDA approval for its topical presbyopia eye drop and simultaneously closed financing of approximately $235 million in combined debt and equity to support commercialization. The approval clears Tenpoint to enter a competitive market for pharmacologic presbyopia treatments. Tenpoint’s product will launch into a commercial environment that already includes approvals from large ophthalmology players; the company said the new funding will support marketing and market access. Presbyopia drops are topical optical medicines intended to temporarily improve near vision by modulating pupil or lens dynamics; their commercial success depends on patient adoption and reimbursement.